Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for diseases or other public health threats for civilian, government and military use. Co.'s U.S. Food and Drug Administration approved commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens. SEYSARA® (sarecycline) is being marketed by Almirall, LLC in the U.S. as a new once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The PRTK stock yearly return is shown above.
The yearly return on the PRTK stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2013 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRTK annual return calculation with any dividends reinvested as applicable (on ex-dates).
|